These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 31836501

  • 1. Magnesium: An old player revisited in the context of CKD-MBD.
    Pendón-Ruiz de Mier MV, Rodelo-Haad C, Díaz-Tocados JM, Muñoz-Castañeda JR, Rodríguez M.
    Clin Chim Acta; 2020 Feb; 501():53-59. PubMed ID: 31836501
    [Abstract] [Full Text] [Related]

  • 2. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
    Neven E, Vervaet B, Brand K, Gottwald-Hostalek U, Opdebeeck B, De Maré A, Verhulst A, Lalau JD, Kamel S, De Broe ME, D'Haese PC.
    Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
    [Abstract] [Full Text] [Related]

  • 3. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.
    Liabeuf S, McCullough K, Young EW, Pisoni R, Zee J, Reichel H, Pecoits-Filho R, Port FK, Stengel B, Csomor PA, Metzger M, Robinson B, Massy ZA.
    Bone; 2019 Dec; 129():115058. PubMed ID: 31493530
    [Abstract] [Full Text] [Related]

  • 4. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, Kramer H.
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [Abstract] [Full Text] [Related]

  • 5. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
    Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.
    Kidney Int; 2017 Jul; 92(1):26-36. PubMed ID: 28646995
    [Abstract] [Full Text] [Related]

  • 6. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
    Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC.
    J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
    [Abstract] [Full Text] [Related]

  • 7. Mineral metabolism and cardiovascular disease in CKD.
    Fujii H, Joki N.
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cy/+ rats.
    Vorland CJ, Lachcik PJ, Swallow EA, Metzger CE, Allen MR, Chen NX, Moe SM, Hill Gallant KM.
    Sci Rep; 2019 May 28; 9(1):7936. PubMed ID: 31138895
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce.
    McAlister L, Pugh P, Greenbaum L, Haffner D, Rees L, Anderson C, Desloovere A, Nelms C, Oosterveld M, Paglialonga F, Polderman N, Qizalbash L, Renken-Terhaerdt J, Tuokkola J, Warady B, Walle JV, Shaw V, Shroff R.
    Pediatr Nephrol; 2020 Mar 28; 35(3):501-518. PubMed ID: 31667620
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?
    Cozzolino M, Ureña-Torres P, Vervloet MG, Brandenburg V, Bover J, Goldsmith D, Larsson TE, Massy ZA, Mazzaferro S, CKD-MBD Working Group of ERA-EDTA.
    Nephrol Dial Transplant; 2014 Oct 28; 29(10):1815-20. PubMed ID: 24516228
    [Abstract] [Full Text] [Related]

  • 15. The role of activin: the other side of chronic kidney disease-mineral bone disorder?
    Cianciolo G, La Manna G, Capelli I, Gasperoni L, Galassi A, Ciceri P, Cozzolino M.
    Nephrol Dial Transplant; 2021 May 27; 36(6):966-974. PubMed ID: 32940690
    [Abstract] [Full Text] [Related]

  • 16. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J, Ureña-Torres P, Lloret MJ, Ruiz-García C, DaSilva I, Diaz-Encarnacion MM, Mercado C, Mateu S, Fernández E, Ballarin J.
    Expert Opin Pharmacother; 2016 Jun 27; 17(9):1247-58. PubMed ID: 27156993
    [Abstract] [Full Text] [Related]

  • 17. A feline-focused review of chronic kidney disease-mineral and bone disorders - Part 2: Pathophysiology of calcium disorder and extraosseous calcification.
    Tang PK, Geddes RF, Jepson RE, Elliott J.
    Vet J; 2021 Sep 27; 275():105718. PubMed ID: 34329743
    [Abstract] [Full Text] [Related]

  • 18. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D'Avino R, De Leon J.
    Atherosclerosis; 2018 Nov 27; 278():49-59. PubMed ID: 30253289
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.